Literature DB >> 11748987

Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium.

Rainer Lehner1, Takayuki Enomoto, James A McGregor, A Laurie Shroyer, Bryan R Haugen, Umarani Pugazhenthi, Kenneth R Shroyer.   

Abstract

OBJECTIVES: In the current study, the quantitative levels of telomerase hTERT mRNA and the functional telomerase repeat amplification protocol (TRAP) assay were correlated with tumor grade in endometrial carcinomas and with the histologic phase of normal endometrium.
METHODS: Twenty-six samples of endometroid adenocarcinoma and 20 cases of benign endometrium were obtained from hysterectomy specimens. Total RNA was extracted from each tissue sample and used for quantitative real-time RT-PCR of hTERT mRNA and the levels were standardized to the levels of ribosomal RNA. Quantitative determination of telomerase activity was performed by the polymerase chain-based TRAP assay and the levels of expression were defined by the ratio of radioactivity incorporated into the 6-bp telomerase amplification products versus the radioactivity incorporated into an internal standard (telomerase/ITAS x 100 = 1 RU). Statistical analyses were performed using the Fisher exact test or chi2 test, a Wilcoxon rank sum test, and a linear regression analysis.
RESULTS: hTERT mRNA and telomerase activity levels showed a linear association in the study group (P = 0.006, R2 = 0.139). hTERT mRNA levels and telomerase activity levels were significantly higher in endometrial cancer (179 pg/ng rRNA, 44 relative units (RU)) than in normal endometrium (45 pg/ng), (15 RU) (P = 0.009, P = 0.006). In normal endometrium, hTERT mRNA and telomerase activity levels were highest in the proliferative phase (74 pg/ng rRNA, 25 RU) and were relatively low in secretory (13 pg/ng rRNA, 6 RU) and atrophic endometrium (9 pg/ng rRNA, 2 RU).
CONCLUSION: These results suggest that the quantitative analysis of hTERT and telomerase activity may have potential roles as diagnostic or prognostic adjuncts for both premenopausal and postmenopausal patients with endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748987     DOI: 10.1006/gyno.2001.6474

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Effect of vector-expressed shRNAs on hTERT expression.

Authors:  Ying Guo; Jun Liu; Ying-Hui Li; Tian-Bao Song; Jing Wu; Cai-Xia Zheng; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

2.  Organ Specific Tumor Markers: What's New?

Authors:  Kannan Vaidyanathan; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2011-11-08

3.  Krüppel-like factor 9 loss-of-expression in human endometrial carcinoma links altered expression of growth-regulatory genes with aberrant proliferative response to estrogen.

Authors:  Christian D Simmons; John Mark P Pabona; Melissa E Heard; Theodore M Friedman; Michael T Spataro; Amy L Godley; Frank A Simmen; Alexander F Burnett; Rosalia C M Simmen
Journal:  Biol Reprod       Date:  2011-05-04       Impact factor: 4.285

4.  Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage.

Authors:  Kiyoko Kato; Tomoka Takao; Ayumi Kuboyama; Yoshihiro Tanaka; Tatsuhiro Ohgami; Shinichiro Yamaguchi; Sawako Adachi; Tomoko Yoneda; Yousuke Ueoka; Keiji Kato; Shinichi Hayashi; Kazuo Asanoma; Norio Wake
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

5.  hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors.

Authors:  Xing Fan; Yunyue Wang; John Kratz; Dan J Brat; Yves Robitaille; Albert Moghrabi; Elizabeth J Perlman; Chi V Dang; Peter C Burger; Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

6.  Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Authors:  Esra A Akbay; Cristina M Contreras; Samanthi A Perera; James P Sullivan; Russell R Broaddus; John O Schorge; Raheela Ashfaq; Hossein Saboorian; Kwok-Kin Wong; Diego H Castrillon
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

7.  The status of telomerase enzyme activity in benign and malignant gynaecologic pathologies.

Authors:  Ilhami Gül; Ozgür Dündar; Serkan Bodur; Yusuf Tunca; Levent Tütüncü
Journal:  Balkan Med J       Date:  2013-09-01       Impact factor: 2.021

8.  Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cells.

Authors:  Chunxiao Zhou; Tara A Steplowski; Hallum K Dickens; Kimberly M Malloy; Paola A Gehrig; John F Boggess; Victoria L Bae-Jump
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

9.  Peroxisome proliferator-activated receptor γ agonist suppresses human telomerase reverse transcriptase expression and aromatase activity in eutopic endometrial stromal cells from endometriosis.

Authors:  Hye Jin Chang; Jae Hoon Lee; Kyung Joo Hwang; Mi Ran Kim; Jung Hyun Yoo
Journal:  Clin Exp Reprod Med       Date:  2013-06-30

10.  Knockdown of hTERT and Treatment with BIBR1532 Inhibit Cell Proliferation and Invasion in Endometrial Cancer Cells.

Authors:  Weimin Kong; Nenan Lv; Weiya Z Wysham; Dario R Roque; Tongqing Zhang; Simeng Jiao; Dan Song; Jiao Chen; Victoria L Bae-Jump; Chunxiao Zhou
Journal:  J Cancer       Date:  2015-11-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.